Nandi Tania, Pradyuth Sai, Singh Arihant Kumar, Chitkara Deepak, Mittal Anupama
Department of Pharmacy, Birla Institute of Technology and Science (BITS PILANI), Pilani, Rajasthan, 333031, India.
Department of Pharmacy, Birla Institute of Technology and Science (BITS PILANI), Pilani, Rajasthan, 333031, India.
Drug Discov Today. 2020 Sep 16. doi: 10.1016/j.drudis.2020.09.008.
Desmoplasia is a major barrier to chemotherapy in several cancers, particularly pancreatic ductal adenocarcinoma and breast cancer. Tumors comprise of cellular and noncellular components and chemoresistant cancer stem cells (CSCs) with established signaling pathways. In this review, we discuss drugs, such as pentoxifylline, aspirin, and metformin, that have been repurposed and investigated for their antidesmoplastic activity in combination with antitumor drugs. We also highlight less explored new small-molecule drugs, and gene and peptide-based therapeutics for the treatment of desmoplasia and to target CSCs. Promising results from preclinical studies have encouraged several clinical trials to evaluate these antidesmoplastic agents as adjunct to chemotherapy.
促结缔组织增生在多种癌症（尤其是胰腺导管腺癌和乳腺癌）中是化疗的主要障碍。肿瘤由细胞和非细胞成分以及具有既定信号通路的化疗耐药性癌症干细胞（CSCs）组成。在本综述中，我们讨论了已被重新利用并研究其与抗肿瘤药物联合使用时抗促结缔组织增生活性的药物，如己酮可可碱、阿司匹林和二甲双胍。我们还重点介绍了较少被探索的新型小分子药物以及基于基因和肽的疗法，用于治疗促结缔组织增生和靶向癌症干细胞。临床前研究的 promising 结果促使多项临床试验将这些抗促结缔组织增生药物作为化疗辅助药物进行评估。 （注：“promising”原意为“有希望的、有前途的” ，这里翻译为“有前景的” ，为使译文更通顺，调整为“有希望的” ）
